Immune checkpoint inhibitors (ICIs) work by inhibiting the interaction between immune checkpoints, such as PD-1 and CTLA-4, and their ligands, thus preventing the immune escape of tumor cells, boosting the activity of T cells, and improving anti-tumor immune memory (10, 11). Here, PDCD1 is linked to neoplasm.